SUPNSUPERNUS PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $719M
- 8.6% YoY
- Operating margin
- -8.7%
- 170% YoY
- EBITDA
- $29M
- 82% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -5.2×
- −$153M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $580M | $667M | $608M | $662M | $719M | 8.6% |
| Operating income | $86M | $46M | −$5M | $82M | −$62M | 176% |
| Net income | $53M | $61M | $1M | $74M | −$39M | 152% |
| Operating cash flow | $127M | $117M | $111M | $172M | $47M | 72% |
| Capex | — | $412K | $551K | $725K | $1M | 85% |
| Stock-based comp | $18M | $18M | $27M | $28M | $33M | 19% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $87K · 1
- Net
- −$87K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $16M | $24M | 198 | 125 |
| FY2024 | $13M | $9M | 144 | 93 |
| FY2023 | $13M | $13M | 115 | 94 |
| FY2022 | $10M | $11M | 142 | 90 |
| FY2021 | $8M | $8M | 116 | 100 |